SCHEDULE 13G/A: Millennium Management Discloses 3.8% Stake in ANI Pharmaceuticals

Millennium Management LLC and its affiliates have reported a 3.8% beneficial ownership stake in ANI Pharmaceuticals, Inc. as of March 31, 2025.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership of 818,341 shares of ANI Pharmaceuticals, Inc. common stock.
• This ownership represents 3.8% of the total outstanding common stock of ANI Pharmaceuticals, Inc.
• The reporting persons hold shared voting power and shared dispositive power over all 818,341 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• A significant institutional investor, Millennium Management LLC, has disclosed a 3.8% stake in ANI Pharmaceuticals, Inc., which can be viewed as a vote of confidence in the company.

Future Outlook

No forward-looking statements or guidance regarding ANI Pharmaceuticals, Inc. are provided in this beneficial ownership filing.

Industry Context

This filing is a standard regulatory disclosure of a significant ownership stake by an investment firm in a publicly traded pharmaceutical company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake can influence market perception and potentially the share price of ANI Pharmaceuticals, Inc.

Key Dates

Keywords

ANI Pharmaceuticals, Millennium Management, Schedule 13G, beneficial ownership, institutional investment, common stock, equity stake